OR2M7 Antibody

What is OR2M7 and why is it significant for olfactory research?

OR2M7 (Olfactory Receptor Family 2 Subfamily M Member 7) is a G-protein-coupled receptor involved in olfactory signal transduction. It's one of approximately 400 different types of olfactory receptors located on specialized neurons in the nasal cavity. This receptor is particularly significant because it's associated with the detection of specific odors, including the ability to detect the distinctive smell produced in urine after consuming asparagus. Research involving OR2M7 contributes to our understanding of the genetic basis of olfactory perception variation among individuals .

What are the key specifications of commercially available OR2M7 antibodies?

Most commercially available OR2M7 antibodies share the following specifications:

This information is critical for experiment planning and selection of appropriate antibody reagents .

What experimental applications are validated for OR2M7 antibodies?

OR2M7 antibodies have been validated for multiple experimental applications:

• Western Blot (WB): Used for detecting OR2M7 protein in cell lysates with recommended dilutions typically between 1:500-1:2000.

• Immunofluorescence/Immunocytochemistry (IF/ICC): Used for visualizing OR2M7 localization in cells with recommended dilutions typically between 1:200-1:1000.

• ELISA: Used for quantitative detection of OR2M7, with recommended dilutions around 1:10000.

• Immunohistochemistry (IHC): Some antibodies have been validated for tissue staining .

Each application requires specific optimization for signal-to-noise ratio and specificity validation.

How can OR2M7 antibodies be validated for cross-reactivity with other olfactory receptor family members?

Validating OR2M7 antibody specificity requires multiple approaches to ensure no cross-reactivity with other olfactory receptor family members:

• Epitope Analysis: Perform bioinformatic analysis of the immunogen sequence against other olfactory receptors to identify potential cross-reactive epitopes.

• Knockout/Knockdown Controls: Use CRISPR-Cas9 OR2M7 knockout cells or siRNA knockdown samples as negative controls.

• Peptide Competition Assay: Pre-incubate the antibody with excess immunizing peptide before application to samples - specific signals should be abolished.

• Heterologous Expression Systems: Test antibody reactivity against cells overexpressing OR2M7 versus cells expressing other closely related olfactory receptors.

• Mass Spectrometry Validation: Perform immunoprecipitation followed by mass spectrometry to confirm the identity of the pulled-down protein.

This comprehensive validation is critical because the olfactory receptor gene family is the largest in the genome with nearly 1,000 genes coding for olfactory proteins, making specificity a significant challenge .

What are the methodological considerations for detecting OR2M7 in native tissues versus heterologous expression systems?

Detection of OR2M7 presents different challenges depending on the experimental system:

Native Tissues:

• Expression levels are typically low, requiring signal amplification methods

• High background from other olfactory receptors necessitates careful blocking optimization

• Fixation protocols must preserve transmembrane protein structure (mild fixation recommended)

• Antigen retrieval may be necessary but must be optimized to avoid epitope destruction

• Fresh or flash-frozen tissue samples yield better results than paraffin-embedded sections

Heterologous Expression Systems:

• Overexpression can lead to misfolding and aggregation, creating artifacts

• Fusion tags may interfere with antibody binding sites

• Membrane trafficking in non-native cells may differ from olfactory neurons

• Expression level validation using qPCR is recommended before antibody detection

• Detergent selection for extraction is critical (mild non-ionic detergents like 0.5% NP-40 or 1% Triton X-100 recommended)

Researchers should implement appropriate controls for each system to ensure reliable interpretation of results .

How do recent developments in de novo antibody design technology impact research on olfactory receptors like OR2M7?

Recent breakthroughs in de novo antibody design technology have significant implications for OR2M7 research:

• Atomically Precise Targeting: Fine-tuned RFdiffusion networks can now design antibodies with atomic-level precision to specific epitopes, allowing targeting of previously inaccessible regions of OR2M7.

• Structural Insights: Cryo-EM confirmation of the proper Ig fold and binding pose of designed antibodies enables more precise structural studies of OR2M7's conformation and binding mechanisms.

• Epitope-Specific Binding: Computational design enables creation of antibodies that target specific functional domains of OR2M7, facilitating studies of structure-function relationships.

• Reduced Cross-Reactivity: De novo designed antibodies can be optimized for reduced cross-reactivity with other olfactory receptors, addressing a major challenge in the field.

• Affinity Maturation: Techniques like OrthoRep enable rapid evolution of designed antibodies to achieve single-digit nanomolar affinities while maintaining epitope specificity.

These advances are particularly valuable for studying GPCRs like OR2M7, which have historically been challenging targets for conventional antibody development approaches .

What are the optimal conditions for Western blot detection of OR2M7?

For optimal Western blot detection of OR2M7, follow these methodological guidelines:

• Sample Preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Include 1% SDS to ensure complete solubilization of the membrane protein

  • Avoid boiling samples (heat at 37°C for 30 minutes instead to prevent aggregation)

• Gel Selection:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Consider gradient gels (4-15%) for better separation

• Transfer Conditions:

  • Transfer at low voltage (30V) overnight at 4°C

  • Use PVDF membrane (0.45 μm pore size) pre-activated with methanol

  • Include 0.05% SDS in transfer buffer to facilitate movement of hydrophobic proteins

• Blocking:

  • 5% non-fat dry milk or 3% BSA in TBST (with 0.1% Tween-20)

  • Block for 2 hours at room temperature or overnight at 4°C

• Antibody Incubation:

  • Primary antibody dilution: 1:500 to 1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Secondary antibody dilution: 1:5000 to 1:10000

• Detection:

  • Use enhanced chemiluminescence for best results

  • Exposure time may need to be extended (up to 5 minutes) due to potentially low expression

• Controls:

  • Include OR2M7-overexpressing cell lysate as positive control

  • Pre-incubate antibody with immunizing peptide as specificity control

These recommendations are based on the typical characteristics of GPCR membrane proteins and the specific properties of available OR2M7 antibodies .

What immunofluorescence protocols yield optimal results for OR2M7 localization studies?

For successful immunofluorescence localization of OR2M7, implement the following methodological approach:

• Cell/Tissue Preparation:

  • For cultured cells: Fix with 4% paraformaldehyde for 10 minutes at room temperature

  • For tissue sections: Use fresh-frozen sections (8-10 μm) rather than paraffin-embedded

  • Mild permeabilization: 0.1% Triton X-100 for 5 minutes (excessive permeabilization can destroy membrane epitopes)

• Blocking:

  • Block with 5-10% normal serum (from the same species as secondary antibody) with 1% BSA

  • Add 0.1% saponin to blocking buffer to improve antibody access to membrane proteins

  • Block for 1 hour at room temperature

• Antibody Incubation:

  • Dilute primary antibody 1:200 to 1:1000 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • Use fluorophore-conjugated secondary antibody at 1:500 dilution

  • Include 0.1% saponin in antibody diluent

• Counterstaining and Mounting:

  • DAPI (1 μg/ml) for nuclear staining

  • Consider membrane counterstains (CellMask, WGA) for colocalization studies

  • Mount with anti-fade mounting medium to preserve fluorescence

• Controls and Validation:

  • Peptide competition control to verify specificity

  • Secondary-only control to assess background

  • Colocalization with ER or Golgi markers to confirm expected subcellular distribution

  • Z-stack imaging to verify membrane localization pattern

• Image Acquisition:

  • Use confocal microscopy for optimal resolution of membrane localization

  • Employ deconvolution algorithms to enhance signal clarity

  • Standardize exposure settings across experimental conditions

This protocol accounts for the challenges associated with membrane protein detection while maximizing specific signal for OR2M7 .

How should researchers approach epitope mapping for novel OR2M7 antibodies?

A comprehensive epitope mapping strategy for OR2M7 antibodies should include multiple complementary approaches:

• In Silico Analysis:

  • Begin with bioinformatic prediction of immunogenic epitopes on OR2M7

  • Compare the immunizing peptide sequence with the full OR2M7 sequence

  • Identify potential linear and conformational epitopes using algorithms like BepiPred or Ellipro

• Peptide Array Analysis:

  • Synthesize overlapping peptides (15-20 amino acids with 5-amino acid overlap) spanning the entire OR2M7 sequence

  • Spot peptides onto membranes and probe with the antibody

  • Identify reactive peptides to pinpoint linear epitopes

• Truncation/Deletion Mutants:

  • Generate a series of OR2M7 truncation constructs

  • Express in mammalian cells and analyze binding by Western blot or immunoprecipitation

  • Narrow down the region containing the epitope

• Alanine Scanning Mutagenesis:

  • Once the approximate epitope region is identified, create point mutations where key residues are substituted with alanine

  • Test antibody binding to identify critical binding residues

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

  • For conformational epitopes, employ HDX-MS to identify regions protected from deuterium exchange when the antibody is bound

  • This approach is particularly valuable for membrane proteins like OR2M7

• Cross-Competition Assays:

  • If multiple OR2M7 antibodies are available, perform cross-competition assays

  • Determine if antibodies compete for binding or can bind simultaneously

• Structural Analysis:

  • If resources permit, X-ray crystallography or cryo-EM of the antibody-antigen complex provides definitive epitope information

  • Recent advances in computational antibody design can also provide structural insights

This multi-faceted approach provides comprehensive epitope characterization, which is essential for understanding antibody specificity and functionality in OR2M7 research .

What are the most common causes of false negative results when detecting OR2M7, and how can they be addressed?

False negative results in OR2M7 detection can stem from several technical issues:

• Protein Extraction Issues:

  • Problem: Inadequate solubilization of the transmembrane protein

  • Solution: Use stronger lysis buffers containing 1-2% SDS or 4M urea; consider specialized membrane protein extraction kits

• Epitope Masking/Destruction:

  • Problem: Fixation or sample preparation destroying or masking the C-terminal epitope

  • Solution: Test multiple fixation protocols; reduce fixation time; use milder fixatives (1-2% PFA instead of 4%)

• Low Expression Levels:

  • Problem: Endogenous OR2M7 expression below detection threshold

  • Solution: Implement signal amplification methods (TSA, ABC method); increase antibody concentration; extend incubation times; use more sensitive detection systems

• Protein Misfolding in Heterologous Systems:

  • Problem: Incorrectly folded protein in overexpression systems

  • Solution: Use specialized mammalian expression systems designed for GPCRs; employ molecular chaperones; test expression at lower temperatures

• Buffer Incompatibility:

  • Problem: Buffer components interfering with antibody binding

  • Solution: Test multiple buffer systems; reduce detergent concentration; eliminate potential interfering agents

• Antibody Degradation:

  • Problem: Loss of antibody activity during storage

  • Solution: Aliquot antibody upon receipt; strictly avoid freeze-thaw cycles; validate activity with positive controls before each experiment

• Inappropriate Application Parameters:

  • Problem: Suboptimal dilution or incubation conditions

  • Solution: Perform careful titration experiments; test extended incubation times (24-48 hours at 4°C)

Each of these interventions should be systematically tested to optimize detection of OR2M7, particularly in systems with native expression levels .

How can researchers distinguish between specific and non-specific binding when using OR2M7 antibodies?

Discriminating between specific and non-specific binding is crucial for OR2M7 antibody research. Implement these validation strategies:

• Molecular Weight Verification:

  • OR2M7 should appear at approximately 35-40 kDa on Western blots

  • Non-specific bands at different molecular weights should be documented and investigated

• Comprehensive Controls:

  • Peptide Competition: Pre-incubation with immunizing peptide should abolish specific signal

  • Knockout/Knockdown Samples: CRISPR knockout or siRNA knockdown samples should show reduced or absent signal

  • Overexpression: OR2M7-transfected cells should show enhanced signal at the correct molecular weight

• Multiple Antibody Validation:

  • Use at least two antibodies targeting different epitopes of OR2M7

  • Concordance of signal between different antibodies increases confidence in specificity

• Tissue/Cell Type Specificity Check:

  • Compare signal in tissues known to express OR2M7 versus those that don't

  • Pattern should match mRNA expression data from public databases

• Signal Quantification and Thresholding:

  • Implement quantitative analysis of signal-to-noise ratio

  • Establish clear thresholds for distinguishing specific from background signal

• Secondary Antibody-Only Controls:

  • Include controls with secondary antibody alone to identify non-specific binding

  • Match concentration and incubation conditions to experimental samples

• Method-Specific Validation:

  • For immunofluorescence: Compare membrane localization pattern against known GPCR markers

  • For Western blot: Compare migration pattern to predicted molecular weight accounting for post-translational modifications

  • For immunoprecipitation: Confirm pulled-down protein identity by mass spectrometry

These systematic validation steps help ensure research findings reflect true OR2M7 biology rather than artifacts .

What strategies can overcome the challenges of detecting low-abundance OR2M7 protein in native tissues?

Detecting low-abundance OR2M7 in native tissues requires specialized approaches:

• Sample Enrichment Techniques:

  • Subcellular Fractionation: Isolate membrane fractions to concentrate OR2M7

  • Immunoprecipitation: Use high-affinity capture antibodies followed by detection with a different OR2M7 antibody

  • Lectin-Based Enrichment: Exploit glycosylation of OR2M7 for selective enrichment

• Signal Amplification Methods:

  • Tyramide Signal Amplification (TSA): Can increase sensitivity 10-100 fold

  • Rolling Circle Amplification (RCA): For single-molecule sensitivity in tissue sections

  • Proximity Ligation Assay (PLA): For detecting protein-protein interactions involving OR2M7

• Enhanced Detection Systems:

  • Super-Resolution Microscopy: STORM or PALM for detecting sparse membrane proteins

  • Highly Sensitive ELISA: Use biotin-streptavidin systems with chemiluminescent substrates

  • Nano-LC-MS/MS: For proteomic detection with targeted mass spectrometry methods (PRM/MRM)

• Optimized Tissue Preparation:

  • Use fresh-frozen rather than fixed tissues when possible

  • Employ mild fixation protocols specifically optimized for membrane proteins

  • Consider specialized tissue clearing techniques for 3D visualization

• Gene Editing Approaches:

  • CRISPR knock-in of epitope tags or fluorescent proteins

  • Creation of reporter constructs under endogenous promoter control

• Indirect Detection Strategies:

  • Measure functional responses correlated with OR2M7 activity

  • Use labeled ligands to identify active receptor

• Computational Enhancement:

  • Employ deconvolution algorithms to enhance signal quality

  • Use machine learning for automated signal detection and quantification

These approaches can significantly improve detection of native OR2M7, enabling more physiologically relevant studies of its expression and function .

How can OR2M7 antibodies contribute to understanding the genetic basis of olfactory perception variation?

OR2M7 antibodies provide crucial tools for investigating olfactory perception genetics:

• Genotype-Phenotype Correlation Studies:

  • Quantify OR2M7 protein expression in individuals with different genetic variants

  • Correlate protein levels with specific olfactory perception phenotypes (e.g., asparagus odor detection)

  • Use immunohistochemistry to compare receptor distribution in nasal tissue from individuals with different perceptual abilities

• Receptor Trafficking Analysis:

  • Examine how genetic variants affect receptor localization to cilia

  • Compare membrane versus intracellular distribution of variant receptors

  • Investigate protein stability and turnover rates of different variants

• Structural Biology Applications:

  • Use antibodies to stabilize receptor conformations for structural studies

  • Facilitate crystallization of OR2M7 for X-ray crystallography

  • Enable purification for cryo-EM structural analysis

• Signaling Mechanism Investigation:

  • Study how genetic variants affect OR2M7 coupling to G-proteins

  • Examine receptor internalization and desensitization mechanisms

  • Investigate formation of receptor complexes and their composition

• Developmental Expression Patterns:

  • Track OR2M7 expression during embryonic and postnatal development

  • Correlate developmental expression with acquisition of specific olfactory abilities

  • Study the impact of early environmental exposures on receptor expression

• Population Genetics Research:

  • Compare OR2M7 protein expression across different ethnic populations

  • Investigate evolutionary selection pressures on receptor structure and function

  • Examine the relationship between genetic diversity and olfactory perception diversity

These applications provide mechanistic insights into how genetic variation in OR2M7 translates to perceptual differences among individuals, contributing to our understanding of human sensory diversity .

What is the significance of OR2M7 in the context of recent advancements in de novo antibody design technology?

OR2M7 represents an important target for demonstrating the capabilities of new antibody design technologies:

• Challenging Target Validation:

  • As a GPCR with 7 transmembrane domains, OR2M7 exemplifies a difficult antibody target class

  • Successfully designing antibodies against specific OR2M7 epitopes validates the technology for other membrane proteins

• Structure-Based Design Applications:

  • Fine-tuned RFdiffusion networks can design antibodies targeting specific functional domains of OR2M7

  • Computational approaches can predict binding modes with atomic-level precision

  • Successful binding validates the accuracy of the computational models

• Conformational Selectivity Development:

  • Design antibodies that selectively recognize active versus inactive conformations of OR2M7

  • Create antibodies that stabilize specific receptor states for structural studies

  • Develop tools to study conformational changes during receptor activation

• Epitope-Specific Tool Generation:

  • Create a panel of antibodies targeting different domains for comprehensive receptor characterization

  • Design antibodies that distinguish between closely related olfactory receptors

  • Develop tools for studying receptor heterodimers or oligomeric complexes

• Therapeutic Potential Exploration:

  • While primarily a research tool, OR2M7 antibodies demonstrate proof-of-concept for designing antibodies against other GPCRs with therapeutic potential

  • Technology validated on OR2M7 can be applied to drug targets in the same protein family

The successful application of de novo antibody design to OR2M7 demonstrates the potential of this technology for creating previously impossible research tools for challenging membrane protein targets .

A5.3. How might OR2M7 antibodies be integrated into multi-omics research approaches?

OR2M7 antibodies can serve as valuable components in integrated multi-omics research strategies:

• Proteogenomic Integration:

  • Correlate OR2M7 protein expression (detected by antibodies) with transcriptomic data

  • Investigate post-transcriptional regulation by comparing protein and mRNA levels

  • Examine the impact of genetic variants on protein expression and modification

• Spatial Omics Applications:

  • Use OR2M7 antibodies for spatial proteomics in olfactory tissue

  • Combine with spatial transcriptomics to create comprehensive maps of receptor expression

  • Integrate with lipidomics to study membrane microenvironment effects on receptor function

• Interactome Mapping:

  • Apply antibodies for immunoprecipitation coupled with mass spectrometry

  • Identify protein-protein interaction networks involving OR2M7

  • Compare interactomes across different cell types or physiological states

• Functional Genomics Correlation:

  • Integrate antibody-based protein quantification with CRISPR screening data

  • Identify genes that regulate OR2M7 expression, localization, or function

  • Correlate with functional assay outcomes to build comprehensive models

• Single-Cell Multi-Parameter Analysis:

  • Combine single-cell antibody-based detection with RNA-seq

  • Correlate protein expression with transcriptional profiles at single-cell resolution

  • Study heterogeneity in olfactory neuron populations

• Longitudinal Studies:

  • Track changes in OR2M7 expression over time in response to environmental factors

  • Correlate with metabolomic changes during olfactory adaptation

  • Examine epigenetic modifications in relation to protein expression patterns

• Disease Mechanism Investigation:

  • Apply in studies of olfactory dysfunction in neurodegenerative diseases

  • Correlate receptor changes with broader pathological processes

  • Integrate with clinical data to identify biomarker potential

This multi-omics integration provides a comprehensive view of OR2M7 biology beyond what any single approach could achieve, placing the receptor in its broader biological context .

Technical Data Table: OR2M7 Antibody Specifications and Applications